153 related articles for article (PubMed ID: 35397434)
21. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
22. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
23. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
25. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
[TBL] [Abstract][Full Text] [Related]
26. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
[TBL] [Abstract][Full Text] [Related]
27. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
Muro K; Yoshino T; Doi T; Shirao K; Takiuchi H; Hamamoto Y; Watanabe H; Yang BB; Asahi D
Jpn J Clin Oncol; 2009 May; 39(5):321-6. PubMed ID: 19287023
[TBL] [Abstract][Full Text] [Related]
28. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
29. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
[TBL] [Abstract][Full Text] [Related]
30. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
[TBL] [Abstract][Full Text] [Related]
31. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR; Yang JC; Yu H; Kim SW; Saka H; Horn L; Goto K; Ohe Y; Mann H; Thress KS; Frigault MM; Vishwanathan K; Ghiorghiu D; Ramalingam SS; Ahn MJ
Ann Oncol; 2020 Apr; 31(4):507-516. PubMed ID: 32139298
[TBL] [Abstract][Full Text] [Related]
32. Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.
Heublein S; Mayr D; Egger M; Karsten U; Goletz S; Angele M; Gallwas J; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2015 May; 34(1):50. PubMed ID: 25986064
[TBL] [Abstract][Full Text] [Related]
33. GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.
Gellert J; Jäkel A; Danielczyk A; Goletz C; Lischke T; Flechner A; Dix L; Günzl A; Kehler P
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338686
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
37. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
38. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
Hecht JR; Mitchell E; Neubauer MA; Burris HA; Swanson P; Lopez T; Buchanan G; Reiner M; Gansert J; Berlin J
Clin Cancer Res; 2010 Apr; 16(7):2205-13. PubMed ID: 20332321
[TBL] [Abstract][Full Text] [Related]
39. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Tchaicha J; Kikuchi E; Wong KK; Kufe D
Clin Cancer Res; 2014 Nov; 20(21):5423-34. PubMed ID: 25189483
[TBL] [Abstract][Full Text] [Related]
40. TA-MUC1 epitope in non-small cell lung cancer.
Kuemmel A; Single K; Bittinger F; Faldum A; Schmidt LH; Sebastian M; Micke P; Taube C; Buhl R; Wiewrodt R
Lung Cancer; 2009 Jan; 63(1):98-105. PubMed ID: 18539357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]